<DOC>
	<DOC>NCT01044719</DOC>
	<brief_summary>Cystic Fibrosis patients attending with infective exacerbations will be enrolled into the study. The trial is a double blinded, randomised trial with patients randomised to 10,14 or 21 days of antibiotic therapy, comprising of tobramycin and either ceftazidime or meropenem.</brief_summary>
	<brief_title>Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<criteria>16 years or older Diagnosis of Cystic Fibrosis Presenting with Infective exacerbation Unable to give consent Allergy to study medications Intolerance of aminoglycoside antibiotics Pseudomonas resistant to study antibiotics On the active transplant list or FEV1&lt;20% predicted Pregnancy/breastfeeding Coexistent ABPA requiring a change in treatment Coexistent mycobacterial infection A previous participant in the study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>